Search - tctmd.com

Displaying 61 - 80 of 101

Sort: Relevancy | Date

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

October 29, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

April 29, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Daily News

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

March 01, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

March 01, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

January 18, 2016

News Daily News

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

January 18, 2016

News Daily News

Antiguo Miembro de la FDA Dice que los Datos que Faltan sobre Ensayos Antitrombóticos arrojan una Sombra sobre los Efectos del Fármaco

January 18, 2016

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presentation

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presenter: Jonathan L. Halperin

June 09, 2014

News Daily News

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

April 30, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.